Moderna, Inc.Cambridge, Massachusetts, United States
Disclosure(s): Moderna, Inc.: Employee, Stocks/Bonds (Public Company)
168 - Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an Investigational Respiratory Syncytial Virus Vaccine, in Participants Aged 2 to < 18 Years at High Risk of Severe Disease
Thursday, October 17, 20242:33 PM – 2:45 PM US PT
